Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 10, 22 | -0.11
Increased by
+93.08%
|
-0.10
Decreased by
-10.00%
|
Sep 9, 22 | -0.10
Increased by
+85.51%
|
-0.07
Decreased by
-42.86%
|
May 11, 22 | -0.08 | -0.05
Decreased by
-60.00%
|
Feb 11, 22 | -0.05 | -0.06
Increased by
+16.67%
|
Sep 22, 21 | -1.59 | -0.03
Decreased by
-5.20 K%
|
Jun 21, 21 | -0.69 | -0.04
Decreased by
-1.62 K%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-2.61 M
Decreased by
-68.14%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-2.32 M
Increased by
+92.02%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-1.88 M
Decreased by
-237.60%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-1.07 M
Decreased by
-226.53%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-1.55 M
Decreased by
-505.90%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00 - | -29.11 M - |
Decreased by
N/A%
-
|
Mar 31, 21 | 0.00 - | -555.83 K - |
Decreased by
N/A%
-
|
Dec 31, 20 | 0.00 - | -328.60 K - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.